Literature DB >> 11101195

Isosorbide-2-mononitrate reduces the consequences of myocardial ischaemia, including arrhythmia severity: implications for preconditioning.

K György1, A Végh, M A Rastegar, J G Papp, J R Parratt.   

Abstract

The effects of the intracoronary administration of isosorbide-2-mononitrate (ISMN; 3 microg kg(-1) min(-1)), a major metabolite of isosorbide dinitrate, were examined in chloralose-urethane anaesthetized dogs before and during a 25 min, acute occlusion of the left anterior descending coronary artery. The only significant haemodynamic effects of ISMN administration were a slight (-11 +/- 2 mmHg) decrease in arterial blood pressure and a decrease (< 12%) in diastolic coronary vascular resistance. Coronary occlusion in the presence of ISMN led to a markedly reduced incidence and severity of ventricular arrhythmias compared to those in control, saline-infused dogs. There were fewer ectopic beats (62 +/- 35 versus 202 +/- 72; p < 0.05), a lower incidence (25% versus 75%; p < 0.05) and number of episodes (0.7 +/- 0.4 versus 4.3 +/- 2.1; p < 0.05) of ventricular tachycardia and fewer dogs fibrillated during the ischaemic period (17% versus 82%; p < 0.05). More dogs given ISMN survived the combined ischaemia-reperfusion insult (50% versus 0%; p < 0.05). Changes in ST-segment elevation (recorded by epicardial electrodes) and in the degree of inhomogeneity of electrical activation within the ischaemic area were much less pronounced throughout the occlusion period in dogs given ISMN. These results add weight to the hypothesis that the previously reported antiarrhythmic effects of ischaemic preconditioning, and of the intracoronary administration of nicorandil, involve nitric oxide.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11101195     DOI: 10.1023/a:1007832921391

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  8 in total

1.  The role of nitric oxide, superoxide and peroxynitrite in the anti-arrhythmic effects of preconditioning and peroxynitrite infusion in anaesthetized dogs.

Authors:  Attila Kiss; László Juhász; György Seprényi; Krisztina Kupai; József Kaszaki; Agnes Végh
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

2.  Role of nitric oxide in regulating cardiac electrophysiology.

Authors:  L Wang
Journal:  Exp Clin Cardiol       Date:  2001

3.  Modulation of gap junctions by nitric oxide contributes to the anti-arrhythmic effect of sodium nitroprusside?

Authors:  Márton Gönczi; Rita Papp; Mária Kovács; György Seprényi; Agnes Végh
Journal:  Br J Pharmacol       Date:  2009-02-23       Impact factor: 8.739

4.  A common mechanism in the protective effects of preconditioning, cardiac pacing and physical exercise against ischemia and reperfusion-induced arrhythmias.

Authors:  Agnes Végh; James R Parratt
Journal:  Exp Clin Cardiol       Date:  2005

5.  Peroxynitrite decreases arrhythmias induced by ischaemia reperfusion in anaesthetized dogs, without involving mitochondrial KATP channels.

Authors:  A Kiss; L Juhász; I Huliák; A Végh
Journal:  Br J Pharmacol       Date:  2008-09-01       Impact factor: 8.739

6.  Effect of sodium nitrite on ischaemia and reperfusion-induced arrhythmias in anaesthetized dogs: is protein S-nitrosylation involved?

Authors:  Mária Kovács; Attila Kiss; Márton Gönczi; Gottfried Miskolczi; György Seprényi; József Kaszaki; Mark J Kohr; Elizabeth Murphy; Ágnes Végh
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

7.  Examination of the Changes in Calcium Homeostasis in the Delayed Antiarrhythmic Effect of Sodium Nitrite.

Authors:  Vivien Demeter-Haludka; Mária Kovács; János Prorok; Norbert Nagy; András Varró; Ágnes Végh
Journal:  Int J Mol Sci       Date:  2019-11-13       Impact factor: 5.923

8.  Regulation of gap junctions by nitric oxide influences the generation of arrhythmias resulting from acute ischemia and reperfusion in vivo.

Authors:  Agnes Végh; Márton Gönczi; Gottfried Miskolczi; Mária Kovács
Journal:  Front Pharmacol       Date:  2013-06-14       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.